Stable Response and Sustained Improvement of Itch and Sleep Symptoms in Patients with Atopic Dermatitis Treated with Lebrikizumab over 52 Weeks

• Main Authors: Gil Yosipovitch (Author), Peter Lio (Author), Franz J. Legat (Author), Raj Chovatiya (Author), Mette Deleuran (Author), Evangeline Pierce (Author), Marta Casillas (Author), Yuxin Ding (Author), Fan E. Yang (Author), Laia Bardolet (Author), Sonja Ständer (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2024-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Lebrikizumab demonstrated significant improvement versus placebo for measures of skin clearance and patient-reported outcomes at weeks 16 and 52 in patients with moderate-to-severe atopic dermatitis (AD). We report the sustained impact of lebrikizumab monotherapy, over 52 weeks a...